Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with a less common, but aggressive form of breast cancer.

Gilead Sciences handily beat the consensus Wall Street earnings estimate for Q4. The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech stock.

NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest ...

CHICAGO — Yescarta, the CAR-T therapy made by the Kite unit of Gilead Sciences, prolonged the lives of patients with large B-cell lymphoma by 27% compared to standard treatment in a long-running ...

CymaBay Therapeutics shares jumped nearly 25% and hit a new record high in early trading after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences for $4.3 billion.

But Gilead Sciences, Inc.(NASDAQ:GILD) has fallen short of that second goal, with a share price rise of 32% over five years, which is below the market return.

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while ...

Is Gilead Sciences a smart stock to buy now that Trodelvy is approved to treat a larger audience? Here's what you should know. Trodelvy gets an expansion ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more about GILD stock here.

Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and ...

NEW YORK (Reuters) -Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying kickbacks to doctors who agreed to prescribe its ...

Caption Catarina Frazão Santos, researcher and professor at the Faculty of Sciences of the University of Lisbon and at the Center for Marine and Environmental Sciences (MARE - University of ...